NCT04972656 (TAPE) is a NA clinical trial of Ambrisentan in Pulmonary Arterial Hypertension, sponsored by Nanjing First Hospital, Nanjing Medical University.

Who is sponsoring NCT04972656?

NCT04972656 is sponsored by Nanjing First Hospital, Nanjing Medical University.

What drugs are being tested in NCT04972656?

Interventions in NCT04972656: Ambrisentan, Placebo.

What condition does NCT04972656 study?

NCT04972656 studies Pulmonary Arterial Hypertension.

Is NCT04972656 still recruiting?

NCT04972656 is currently status unknown. Last updated 28 September 2022.

Last reviewed 2022-09-28 · How we verify

NCT04972656: TAPE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension

Status unknown NA Last updated 28 September 2022

What this trial tests

NA trial testing Ambrisentan in Pulmonary Arterial Hypertension in 420 participants. Status unknown.

Timeline

5 September 2022

Primary endpoint
30 December 2025

30 March 2026

Quick facts

Lead sponsor	Nanjing First Hospital, Nanjing Medical University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	420
Start date	5 September 2022
Primary completion	30 December 2025
Estimated completion	30 March 2026
Sites	1 location across China

Drugs / interventions tested

Ambrisentan (AMBRISENTAN) — full drug profile →
Placebo

Conditions studied

Pulmonary Arterial Hypertension — all drugs for Pulmonary Arterial Hypertension →

Sponsor

Nanjing First Hospital, Nanjing Medical University

Who can join

18 and older, any sex, with Pulmonary Arterial Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An Investigator initiated trial (IIT) using a prospective, randomized, double-blind, parallel group, placebo-controlled, clinical study design.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension.
Weatherald J, Fleming TR, Wilkins MR, Cascino TM, et al · · 2024 · cited 11× · PMID 39209468 · DOI 10.1183/13993003.01205-2024
The Management of Mild Pulmonary Hypertension in Clinical Practice.
Zeder K, Brittain E, Kovacs G, Maron BA. · · 2024 · cited 4× · PMID 38747696 · DOI 10.1513/annalsats.202312-1079fr
Selection of Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension: A Comprehensive Narrative Review.
Habib NG, Adhia A, Lopez D, Sandros M, et al · · 2026 · PMID 41348401 · DOI 10.1007/s12325-025-03387-1

Verify or expand the search:

Other trials of Ambrisentan

Trials testing the same drug.

NCT07245680 — COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities · Phase 3 · recruiting
NCT06987097 — Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension · NA · not yet recruiting
NCT04771000 — A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19 · Phase 2 · terminated
NCT04528056 — Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension · Phase 1, PHASE2 · unknown
NCT04393246 — mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms · Phase 2, PHASE3 · completed

Other recruiting trials for Pulmonary Arterial Hypertension

Currently open trials in the same condition.

NCT07391228 — Cognitive Alterations in Pulmonary Arterial Hypertension (PAH) · active not recruiting
NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
NCT07217522 — Rutgers University Study of the Genetics of Pulmonary Hypertension · recruiting
NCT07013149 — The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension · recruiting
NCT06658522 — Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effec · Phase 4 · recruiting

Other Nanjing First Hospital, Nanjing Medical University trials

Trials by the same sponsor.

NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04972656 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
Last refreshed: 28 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04972656.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing